B2BROKER
18.11.2020 12:59:09 CET | Business Wire | Press release
B2Broker , a leading liquidity and technology provider of solutions to the Forex and crypto industry, has announced the launch of B2Margin , a white label margin exchange trading platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118005593/en/
Margin trading, long present in the Forex markets, is now hugely popular in the fast-moving crypto sphere. Even large exchanges have now implemented leveraged trading thanks to its high profit-potential which is not achievable with spot trading these days.
B2Broker CEO and Founder, Arthur Azizov comments, “Margin trading has really increased in popularity despite the fact that derivative trading is what everyone tried to avoid when this was all starting out. Back in 2016, all traders preferred spot trading but business is now moving further towards derivative trading, justifying our decision to develop B2Margin and offer an attractive margin trading solution to our clients”.
Crypto margin trading offers brokers several compelling advantages in terms of more trading opportunities. The threat of exchange hacks is also minimised since trading with leverage reduces the amount of capital that is required to be held by an exchange.
About B2Margin
B2Margin is a White Label Margin Exchange trading platform developed by B2Broker that includes a range of functions including on-boarding, compliance, risk management, pricing and trading analytics.
Offering traders the opportunity to boost their trading with leverage, B2Margin is designed with both institutional and retail clients in mind, supporting multiple asset classes, such as FX, Metals, Indices, Energies, Stocks, ETFs, Cryptocurrencies CFDs and Spot/Cash Cryptocurrencies, with Futures Cryptocurrencies in the pipeline. This means that every broker will be able to provide two solutions to their clients - either leverage or cash trading on all the asset classes outlined.
Furthermore, B2Broker is in the final stages of completing its dividend distribution module which will allow broker-dealers to provide liquidity for STOs shares and cash equities.
Professional and Adaptive GUI
B2Margin offers a vast range of features with an advanced interface which meets all requirements from beginners to professional traders. By providing a customizable and adaptive layout, end users get to choose what they wish to see according to their needs and preferences. Trading instruments are grouped by classes with a customisable workspace which includes intuitive visualisation of market data, an extensive suite of trading tools and complete branding customisation. Some of the main features include:
Multiple Order Types
B2Margin offers multiple order types to support the most sophisticated trading strategies and provide users with a variety of options on how and when to enter and exit a trade. From Protection orders to Time in Force up to Pending orders, traders have everything they need to manage their trading activity.
Professional Сharts
This enables users to place trades, manage orders and work directly from our integrated charts and utilise a comprehensive suite of drawing tools, as well as over 50 technical indicators to analyze price trends.
Secure Wallets
The ability to withdraw, deposit and store your assets in your personal secure wallet. All assets are securely held in our offline storage system to protect users against any possible risks and threats.
Watchlist
Users have the opportunity to add their favourite instruments to the list and keep an eye on their current prices and 24 hour changes. Orders can then be placed straight from the Watchlist.
Order Book
The list of buy and sell orders organized by price is updated in real time and is an important indicator of market depth, reflecting the trading instrument's likely price trend.
Customised Leverage
For precise risk management, a broker’s clients can set their own custom leverage for each trade order. This is a highly anticipated unique feature that provides a competitive advantage in attracting clients to a business.
Risk Management
Along with the standard way of managing risk known as A-Book or B-Book, B2Margin allows brokers to use C-Book - a highly advanced feature for each broker’s dealing department.
A broker dealer will also be able to customise their spread, markup, swap and commissions for each user, particular accounts and by group.
Tech Support
B2Broker offers all its clients 24/7 technical support.
These features, with the added benefit of detailed account statements to volume trade reports, allow brokers to get complete control over their operations and maximise their business potential.
A Complete Customised Solution in 4 Weeks
A complete B2Margin brokerage solution can be implemented in under 4 weeks once the associated legalities and financial aspects are settled. B2Margin also includes B2Broker’s client traders room solution, B2Core , which allows for client onboarding, processing deposits and withdrawals, KYC and a host of other functions for a successful Brokerage business operation. Finally, B2Margin supports FIX API connection enabling brokers to offer their clients the ultimate in trading performance.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201118005593/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
